XXXVI Congreso SETH

Ponencias 17 4. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014;371(26):2477-87. 5. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;371(26):2488-98. 6. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of inde- terminate potential and its distinction from myelodysplastic syndro- mes. Blood 2015;126(1):9-16. 7. Amorós-Pérez M, Fuster JJ. Clonal hematopoiesis driven by somatic mutations: A new player in atherosclerotic cardiovascular disease. Atherosclerosis 2020;297:120-6. 8. Fuster JJ, Walsh K. Somatic Mutations and Clonal Hematopoiesis: Unexpected Potential New Drivers of Age-Related Cardiovascular Disease. Circ Res 2018;122(3):523-32. 9. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med 2017;377(2):111-21. 10. Bick AG, Pirruccello JP, Griffin GK, et al. Genetic Interleukin 6 Sig- naling Deficiency Attenuates Cardiovascular Risk in Clonal Hemato- poiesis. Circulation 2020;141(2):124-31. 11. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 muta- tions in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012;44(11):1179-81. 12. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011;20(1):11-24. 13. Quivoron C, Couronne L, DellaValleV, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011;20(1):25-38. 14. Ko M, Bandukwala HS, An J, et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 2011;108(35):14566-71. 15. Bick AG, Weinstock JS, Nandakumar SK, et al. Inherited Causes of Clonal Hematopoiesis of Indeterminate Potential in TOPMed Whole Genomes. BioRxiv 2019:782748. 16. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Thera- py with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017;377(12):1119-31. 17. Viana-Huete V, Fuster JJ. Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease. Rev Esp Cardiol (Engl Ed) 2019;72(9):760-6. 18. Svensson EC, Madar A, Campbell CD, et al. Abstract 15111: TET2-Driven Clonal Hematopoiesis Predicts Enhanced Response to Canakinumab in the CANTOS Trial: An Exploratory Analysis. Cir- culation 2018;138(Suppl_1):A15111-A. 19. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventio- nal risk factors in patients with coronary heart disease. JAMA 2003;290(7):898-904. 20. Vernon ST, Coffey S, D’Souza M, et al. ST-Segment-Elevation Myo- cardial Infarction (STEMI) Patients Without Standard Modifiable Cardiovascular Risk Factors-How Common Are They, and What Are Their Outcomes? J Am Heart Assoc 2019;8(21):e013296.